The most consequential retatrutide story this month isn't a trial readout. It's a courtroom argument scheduled for 24 September 2026, and it turns on a question that sounds absurd until you follow the money: how many amino acids does retatrutide actually have? The answer decides whether retatrutide FDA approval arrives via a New Drug Application or a Biologics License Application — and with it, whether Eli Lilly gets five years or twelve years of US market exclusivity.

Here's what's confirmed, what's still open, and what it does (and doesn't) change.

The 39-versus-41 problem

Under US law, a "biological product" includes a protein. The FDA's working definition draws a bright line: a molecule needs more than 40 alpha amino acids in a single chain to count as a protein. Anything at or below that is a drug, not a biologic.

Retatrutide's main backbone runs 39 alpha amino acids. Lilly's position is that a second short chain of two further amino acids is covalently bonded to that backbone, bringing the total to 41 — and that even if you don't count it that way, retatrutide is at minimum "analogous to" a protein, which the statute also covers. In March 2024 the FDA disagreed, reading the word "alpha" as modifying every amino acid in the definition, which puts retatrutide outside the protein category.

Lilly sued the agency in September 2024. The case is Eli Lilly and Company v. Kennedy. The district court split the difference: it declined to disturb the FDA's finding that retatrutide is not a protein, but granted Lilly partial summary judgment on the "analogous to a protein" determination, sending that piece back to the agency. In February 2026 Lilly appealed to the Seventh Circuit, asking the appeals court to go further than the district court did and simply order the FDA to classify retatrutide as a biologic outright. Oral argument is set for 24 September 2026.

Why the label matters more than it sounds

This is not a semantic squabble. A BLA carries 12 years of US regulatory exclusivity; an NDA carries five. For a molecule that analysts have already labelled a potential "trillion-dollar" drug, that gap is worth an enormous amount — and it also determines whether follow-on competitors eventually arrive through the generic pathway or the biosimilar one, which are very different processes.

What the fight does not do is change the evidence. The clinical data sit where they sat: TRIUMPH-1 reported up to 28.3% average body-weight reduction at 80 weeks on the 12mg dose, with 45.3% of participants losing 30% or more of their starting weight. The classification question is about which application form and which exclusivity clock apply — not about whether the trial results clear the bar.

The filing timeline hasn't moved

On its second-quarter earnings call on 5 August 2026, Lilly said the retatrutide Phase 3 package is now complete across obesity, obstructive sleep apnoea and knee osteoarthritis pain, and reaffirmed plans to submit in the first quarter of 2027 — with the company still describing that submission as a BLA. Lilly had previously said it needed additional time to finalise chemistry, manufacturing and controls (CMC) data before filing, which is why the submission lands in 2027 rather than 2026.

So the sequence, as it stands on the public record: appellate argument this month, submission targeted for Q1 2027. Nobody has published a decision date for the Seventh Circuit, and we're not going to invent one.

Does this change anything for Australia?

Honestly, not much — and it's worth saying so plainly rather than manufacturing an angle. This is a dispute about US statutory definitions and US exclusivity periods. It has no bearing on the TGA, which runs its own classification and data-protection rules. Retatrutide remains investigational and not TGA-approved, with Lilly having signalled regulatory filings from 2027. If you want the local picture, that's covered on our Australia page.

The one thing Australians can take from it: the "when can I get this" question has more moving parts than a trial result. Manufacturing sign-off, application type and litigation all sit between good data and a prescription pad. For background on the molecule itself, see what retatrutide is and the safety profile.

Want the next development in your inbox rather than hunting for it? Join the free updates list.

FAQ

Is retatrutide FDA approved?

No. As of September 2026 retatrutide has no marketing authorisation in the United States, and it is also unapproved in the UK, EU and Australia. It remains an investigational medicine available only through clinical trials and a limited Lilly expanded-access programme.

Why is Eli Lilly suing the FDA over retatrutide?

Lilly wants retatrutide classified as a biological product, which would allow a Biologics License Application and 12 years of US exclusivity. The FDA determined it is neither a protein nor analogous to one, which points to a New Drug Application and five years. Oral argument in the appeal is set for 24 September 2026.

When will Lilly file retatrutide for approval?

Lilly reaffirmed on its 5 August 2026 earnings call that it plans to submit retatrutide in the first quarter of 2027, after completing manufacturing and quality-control work. That is a company statement of intent, not a regulatory guarantee.

Does the FDA classification dispute delay retatrutide?

Nothing in the public record says it does. Lilly has kept its Q1 2027 submission target while the appeal proceeds. Whether the classification is resolved before or after filing is not something anyone has publicly confirmed.

Sources

This article is general information, not medical advice. Retatrutide is investigational and not approved by the TGA or the FDA. Speak to a qualified Australian health professional about weight management options. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.